Ácido Zoledrónico Hikma (Zoledronic Acid Monohydrate)

Ácido Zoledrónico Hikma contains zoledronic acid monohydrate for intravenous use, a bisphosphonate prescribed to manage bone conditions. This EU-sourced medication supports bone health by reducing bone turnover. Ideal for patients seeking effective osteoporosis or bone metastasis treatments.

Ácido Zoledrónico Hikma is used to treat and prevent osteoporosis in postmenopausal women and men at high risk of fractures. It also helps manage bone complications from certain cancers, such as multiple myeloma or bone metastases from solid tumors. This medication works by slowing bone loss and improving bone density.

After administration, zoledronic acid helps reduce bone pain and lowers the risk of fractures by stabilizing bone structure. Some patients may experience flu-like symptoms shortly after the infusion, which typically resolve within a few days. Regular use supports long-term bone health and mobility.

This medication should be administered by a healthcare professional in a clinical setting. Patients are advised to stay well-hydrated before and after treatment to reduce the risk of kidney issues. Regular dental check-ups are recommended, as bisphosphonates may affect jaw health in rare cases.

Zoledronic acid may interact with other medications affecting kidney function, such as diuretics or NSAIDs. Combining it with certain chemotherapy drugs or calcium supplements should be done under medical supervision. Alcohol and tobacco use may also impact bone health and treatment efficacy.